EUCTR2011-001094-58-NL进行中（未招募）不适用
Prospective, multi-center, randomized, heparin-controlled dose-finding trial to evaluate the efficacy and safety of rivaroxaban, a direct factor Xa inhibitor, on the background of standard dual antiplatelet therapy to support elective percutaneous coronary intervention (X-Plorer). - X-plorer
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Male or female subject aged 18 years or more with no upper age limit and willing to comply with the protocol.
- •2) Symptomatic coronary artery disease due to undergo an elective (non- emergent) PCI on one or two lesions in the native coronary vessel(s). Cardiac standard troponin at baseline is within the normal limits.
- •3) Subject is able to read and give written informed consent and has signed an informed consent form approved by the Investigator's IRB/IEC after receiving detailed written and oral information prior to any study specific procedures.
- •4) Ability to understand and follow study-related instructions.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 55
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1) Conditions that may increase the risk of the PCI procedure
- •oLesion-specific conditions:
- •-Left main coronary artery disease
- •-Chronic Total Occlusions
- •-Bifurcation lesions involving a contiguous side branch with a
- •diameter bigger or equal to 2.5mm by visual estimate
- •-Three vessel disease requiring treatment of more than 2
- •lesions (no staging is allowed)
- •oClinical condition at screening visit:
- •-ST-segment elevation myocardial infarction within 14 days
- •prior to randomization
- •-New York Heart Association class III or IV congestive heart
- •-Hemodynamic instability
- •-Severe hypertension not adequately controlled by
- •antihypertensive therapy at the time of the study entry (BP
- •> 180/110mmHg)
- •2) Conditions that may increase the risk of bleeding, but are not limited to the following:
- •Active internal bleeding
- •Clinically significant gastrointestinal bleeding within 12
- •months before randomization
- •History of intracranial, intraocular, spinal, or atraumatic
- •intraarticular bleeding
- •History of hemorrhagic stroke
- •Major surgery (including CABG), biopsy of a parenchymal
- •organ, ophthalmic surgery, or serious trauma (including
- •head trauma) within 30 days before randomization
- •Known intracranial neoplasm, cerebral metastases,
- •arteriovenous malformation, or aneurysm at time of screening
- •Known coagulopathy or bleeding diathesis (including
- •congenital bleeding disorders such as von Willebrand’s
- •disease or hemophilia; acquired bleeding disorders; and
- •unexplained clinically significant bleeding disorders)
- •Platelet count <90.000/µl at screening visit
- •Fibrinolytics within 10 days before randomization
- •Any other condition known to increase the risk of bleeding
- •3. Concomitant conditions or diseases, such as:
- •Significant valvular heart disease
- •Calculated creatinine clearance =30 mL/min
- •Known liver disease or high concentrations of ALT (> 3x the
- •upper limit of normal)
- •Known allergy, hypersensitivity or contraindication to aspirin,
- •clopidogrel, heparin, rivaroxaban or contrast media
- •Known HIV infection at time of screening
- •Any other medical condition requiring systemic anticoagulation therapy
- •Lactating/pregnant women
- •Treatment with other investigational drugs or devices within 30 days before enrolment or planned use of investigational drugs or devices during the study
- •Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting of performing study requirements
- •Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator
- •4. Concomitant medication:
- •Current use of anticoagulant drugs including VKA. factor IIa, of Factor Xa inhibitors.
- 另有 3 项未显示
研究者
相似试验
已完成
1 期
A multicenter randomized clinical study of using a three-dimensional printed patient personalized titanium plate in jaw surgeryManagement of dentofacial deformities through an orthognathic surgical interventionSurgeryISRCTN11838566West China Hospital of Stomatology, Sichuan University100
进行中（未招募）
不适用
A study Protocol for patients with relapsed osteosarcomaHigh malignancy grade of osteosarcoma relapseMedDRA version: 14.1Level: PTClassification code 10031296Term: Osteosarcoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001010-42-ITITALIAN SARCOMA GROUP
进行中（未招募）
不适用
A prospective, randomised, multicenter clinical trial investigating the reduction of Calcineurin inhibitor toxicity by means of steroid free long-term immune suppression with Ciclosporin A and Mycophenolat mofetil in children and adolescents after kidney transplantation - Recaltox-1EUCTR2007-001166-33-DEniversitaetsklinikum Erlangen-Nuernberg
已完成
4 期
Prospective, multicenter, randomized controlled trial towards identifying the optimal Cetrotide treatment protocolIVF/ICSI infertility10013356NL-OMON37107niversitair Medisch Centrum Utrecht2,430
招募中
4 期
Clinical Evaluation of Naoxintong Capsule for Improving the Quality of Life of Patients with Nonvalvular Atrial Fibrillation after PCIITMCTR2100004841Fujian Provincial Hospital